Curcumin for Depression

Verdict: Promising but preliminary; not a proven treatment

Curcumin shows a real but modest antidepressant signal in early trials, mostly as an add-on in people who also have other conditions. The evidence is still too thin and the populations too narrow for it to be considered a proven treatment for depression, and it should not replace antidepressants or therapy.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

This earns a Preliminary (B) grade because the human-trial evidence leans positive but is genuinely limited. Two meta-analyses found curcumin beat placebo on depressive symptoms, with a small pooled effect in the larger, more conservative review (PMID 33418373, n=594, SMD -0.32) and a larger effect in another (PMID 31423805, n=531, Hedges' g -0.75) — but the 2021 review explicitly rated the overall quality of evidence as low.

The grade is capped by how the positive results were generated. Most trials are small (under 100 people) and short (6–12 weeks), and the strongest results come from people who also had another illness rather than primary depression: the largest and longest trial was in obese type 2 diabetes patients (PMID 39125295, n=227, 52 weeks), with others in diabetic neuropathy (PMID 31788880) and postpartum women (PMID 40281561). Most designs add curcumin on top of usual care, so it is not established as a standalone treatment.

Regulators and clinics reinforce the caution. EFSA set only a safety intake limit and rejected curcumin health claims, NHS guidance warns against use in liver or biliary disease, and NIH/NCCIH says there is not enough evidence to confirm benefit; Mayo Clinic calls the depression data 'limited,' and psychiatric guidelines do not list it. With drug-interaction and liver-injury safety signals attached, curcumin is best seen as an unproven adjunct, not a substitute for antidepressants or psychotherapy.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.60
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
78%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L3 MechanismPlausibility
0.65
L2 PubMedPrimary literature
0.75
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.6
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

The efficacy and acceptability of curcumin for the treatment of depression or depressive symptoms: A systematic review and meta-analysis
PMID: 33418373 2021 統合分析 n = 594
Finding: Curcumin produced a small but statistically significant reduction in depressive symptoms vs placebo. Pooled SMD = -0.32 (95% CI -0.50 to -0.13), I2 = 15%, n=594. Response rates favored curcumin (OR=3.20, 95% CI 1.28-7.99). Drop-out rates and adverse events did not differ from placebo. Authors graded overall evidence quality as low.
Academic Effect size: [object Object]
View on PubMed
Curcumin for depression: a meta-analysis
PMID: 31423805 2020 統合分析 n = 531
Finding: Pooled Hedges' g = -0.75 (95% CI -1.11 to -0.39, p<0.001) for depression — large effect favoring curcumin add-on to standard care. Anxiety symptom subset (5 trials, n=284): Hedges' g = -2.62 (95% CI -4.06 to -1.17). Authors caution that small individual sample sizes and heterogeneity warrant cautious interpretation.
Academic Effect size: [object Object]
View on PubMed
Curcumin Reduces Depression in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial
PMID: 39125295 2024 RCT (double-blind) n = 227
Finding: Curcumin arm showed significantly greater improvement in PHQ-9 depression severity vs placebo at 12 months (p=0.000001). Mechanistic secondary outcomes: higher serum serotonin, lower IL-1beta, IL-6 and TNF-alpha, and increased antioxidant activity in the curcumin group (all p<0.001). Largest and longest RCT to date in a metabolic-comorbid depressive population.
🟢 High quality Government Effect size: [object Object]
View on PubMed
Beneficial effects of nano-curcumin supplement on depression and anxiety in diabetic patients with peripheral neuropathy: A randomized, double-blind, placebo-controlled clinical trial
PMID: 31788880 2020 RCT (double-blind) n = 80
Finding: Nano-curcumin reduced DASS-21 depression score from 16.7 (SD 3.1) to 15.3 (SD 2.6) vs placebo 17.5 (3.2) -> 17.3 (3.1); between-group p=0.02. Anxiety subscale also improved (p=0.009). Demonstrates that low-dose bioavailable nano-formulation can produce measurable antidepressant signal in subclinical/comorbid depression.
Academic Effect size: [object Object]
View on PubMed
The effect of curcumin on postpartum depression and anxiety in primiparous women: a double-blind randomized placebo-controlled clinical trial
PMID: 40281561 2025 RCT (double-blind) n = 96
Finding: Curcumin 500 mg/day for 8 weeks produced significantly greater reductions in postpartum depression and anxiety scores vs placebo, with improvements in mental-health and quality-of-life secondary outcomes. Extends evidence of curcumin's antidepressant signal into perinatal population; effect size not reported as SMD in abstract.
Academic
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4b EU EFSA
Cautious
the Panel established an ADI for curcumin of 3 mg/kg bw/day source↗
L4c UK NHS
Cautious
Avoid turmeric and curcumin in individuals with bile duct obstruction, cholangitis, liver disease, gallstones, or any biliary disease. source↗
L4d TW TFDA / 衛福部
Cautious
薑黃素每人每日攝取量為每公斤體重0~3毫克,每日不超過200毫克為宜 source↗
L4e WHO
Neutral
Rhizoma Curcumae Longae source↗
L5a NIH Office of Dietary Supplements
Cautious
We don't know enough to definitively conclude if turmeric or curcumin is beneficial for any health purposes. source↗
L5b Mayo Clinic
Cautious
limited data in small studies show its effectiveness in providing some improvement in depression source↗
L5c Cleveland Clinic
Cautious
curcumin may also increase levels of serotonin and dopamine, which are chemicals in your brain that regulate mood and other body functions. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-depression-INT-curcumin-001 繁體中文版 →